AstraZeneca PLC First quarter results 2012

Thursday, 26 April 2012

First quarter results reflect challenging revenue picture. Pipeline strengthened by Amgen collaboration, the agreement to acquire Ardea Biosciences and positive CHMP opinion for FORXIGATM (dapagliflozin) in Europe.

 

First quarter results 2012

Announced on Thursday 26 April 2012

Downloads

Webcast

View the webcast